KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) EBIT Margin (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of EBIT Margin data on record, last reported at 92.28% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 29786.0% year-over-year to 92.28%; the TTM value through Dec 2025 reached 346.15%, down 3818.0%, while the annual FY2025 figure was 346.15%, 3818.0% down from the prior year.
  • EBIT Margin reached 92.28% in Q4 2025 per PACB's latest filing, up from 101.13% in the prior quarter.
  • Across five years, EBIT Margin topped out at 92.28% in Q4 2025 and bottomed at 1154.51% in Q1 2025.
  • Average EBIT Margin over 5 years is 250.12%, with a median of 185.6% recorded in 2021.
  • The widest YoY moves for EBIT Margin: up 37549bps in 2025, down -94487bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 179.56% in 2021, then tumbled by -77bps to 318.37% in 2022, then surged by 53bps to 150.02% in 2023, then tumbled by -160bps to 390.14% in 2024, then soared by 76bps to 92.28% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 92.28% in Q4 2025, 101.13% in Q3 2025, and 112.79% in Q2 2025.